Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.01 0.25 (2.13%) Market Cap: 527.03 Mil Enterprise Value: 442.37 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 56/100

Y-mAbs Therapeutics, Inc. - Special Call Transcript

Dec 11, 2019 / 05:00PM GMT
Release Date Price: $32.99 (-2.22%)
Unidentified Company Representative

Hello, everyone, and thank you very much for showing up today for Y-mAbs' first R&D event. We're very excited and very privileged to have 3 fantastic KOLs present, which doesn't happen very often as they're very busy, and welcome to everyone who's on the webcast. And we will go right into it. And Dr. Mora from Barcelona will be the first to present his slides. So thank you very much for your attention.

Jaume Mora;SJD Barcelona Children;s Hospital

' -

Good afternoon, everyone. Thanks to Y-mAbs for the invitation. I'm happy to share with you the extraordinary experience we've had for the last 2.5 years now using naxitamab for my patients.

And I want to emphasize, to start with, that I am working in Barcelona, currently in Spain. I don't know for how long, but this is yet Spain, meaning Western Europe. Meaning, Western Europe. And I'm saying this because the perspective of my colleagues here in -- I trained in New York and I trained in -- at MSK myself. So the perspective from the U.S. colleagues is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot